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ABSTRACT Randomised controlled trials (RCTs) are the gold standard for evaluating treatment efficacy
in patients with obstructive lung disease. However, due to strict inclusion criteria and the conditions
required for ascertaining statistical significance, the patients included typically represent as little as 5% of
the general obstructive lung disease population. Thus, studies in broader patient populations are becoming
increasingly important. These can be randomised effectiveness trials or observational studies providing
data on real-world treatment effectiveness and safety data that complement efficacy RCTs.
In this review we describe the features associated with the diagnosis of asthma and chronic obstructive
pulmonary disease (COPD) in the real-world clinical practice setting. We also discuss how RCTs and
observational studies have reported opposing outcomes with several treatments and inhaler devices due to
differences in study design and the variations in patients recruited by different study types. Whilst
observational studies are not without weaknesses, we outline recently developed tools for defining markers
of quality of observational studies. We also examine how observational studies are capable of providing
valuable insights into disease mechanisms and management and how they are a vital component of
research into obstructive lung disease.
As we move into an era of personalised medicine, recent observational studies, such as the NOVEL
observational longiTudinal studY (NOVELTY), have the capacity to provide a greater understanding of the
value of a personalised healthcare approach in patients in clinical practice by focussing on standardised
outcome measures of patient-reported outcomes, physician assessments, airway physiology, and blood and
airway biomarkers across both primary and specialist care.
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Intervention trials, such as randomised controlled trials (RCTs), and observational studies, such as registry
studies have, until recently, been perceived as being distinct and mutually exclusive approaches to clinical
research in respiratory medicine, as well as in other fields of medical research. Classical RCTs aim to
establish the safety and efficacy of a treatment in the target patient population [1, 2], whereas classical
epidemiology observational studies aim to ascertain how often diseases occur in different groups of people
and why [3]. Additionally, epidemiological information is used to prepare and evaluate strategies to
prevent illness and as a guide for the management of patients in whom disease has already developed [3].
Real-world observational studies with a prospectively recruited cohort aim to establish the effectiveness
and safety of a treatment compared with others in a more general population of patients in a real-world,
clinical practice setting, both with and without deliberate manipulation or intervention [1]. Furthermore,
real-world studies enable exploratory research in broad patient populations that can be used to generate
hypotheses, improve understanding of various aspects of disease and treatments, provide novel
perspectives and challenge existing paradigms [1, 4].
The aim of this review is to evaluate the strengths and limitations of existing observational studies in
assessing the effectiveness of pharmacological treatment in asthma and/or chronic obstructive pulmonary
disease (COPD), in order to highlight key considerations for ongoing and future observational studies in
obstructive lung disease.
Comparing RCTs with observational real-world studies
Observational studies and classical efficacy RCTs ask distinct research questions and thus employ different
study methodologies and patient populations to answer them. Classical efficacy RCTs aim to compare the
efficacy and safety of treatments within a patient population selected using strict inclusion criteria (e.g.
exclusion of active smokers), with high disease severity (in terms of lung function impairment), good
treatment adherence and good inhaler technique, thereby tightly controlling confounding factors.
Although this level of internal validity and control makes it easier to identify the absolute benefit or lack
of benefit of a treatment, it comes at the cost of external validity [5]; thus, results from efficacy RCTs may
not be broadly generalisable to the wider population of patients with obstructive lung disease. Indeed,
while RCTs remain the gold standard for evaluating treatments [2], the patients they include can represent
as few as 5% of the general asthma/COPD population [6, 7].
In contrast, pragmatic RCTs aim to assess the differential benefit of a treatment in a broader patient
population (e.g. patients with less severe lung function impairment and more comorbidities) in a normal
ecology of care and with less intensive medical supervision compared with efficacy RCTs [8]. However,
pragmatic RCTs still involve a higher organisation of clinical practice than that expected in a real-world
setting.
With less intervention and organisation than efficacy RCTs or pragmatic RCTs, pure observational studies
offer a more practical and cost-effective means to investigate the long-term outcome of a treatment in a
broader patient population than that included in an RCT [5, 8].
As real-world studies differ substantially from efficacy RCTs in their objectives and approach, their study
design often requires different considerations and many more patients are eligible for both pragmatic
RCTs and observational studies compared with efficacy RCTs [1]. Such studies are seen as increasingly
important for understanding treatment effectiveness in a broader patient population [8–11], thereby
potentially informing future treatment management strategies.
Real-world studies can take many forms, including the following.
Classical epidemiological studies, e.g. trajectories of lung function in COPD [12], assessing the association
between sleep-disordered breathing and asthma [13] management, morbidity and mortality of COPD in
Sweden [14] and identifying COPD subtypes and corresponding biomarkers [15].
Retrospective studies using existing, routinely collected health data, such as electronic medical records or
insurance claims, e.g. a study on predicting asthma attacks using real-world primary care data in the
UK [16].
Post-marketing surveillance/phase IV studies monitor the real-world response to newly approved
treatments, including real-world safety and mortality. These studies have helped identify and understand
events such as the increased mortality rates observed amongst patients with asthma who received
salbutamol (in Australia) and fenoterol (in New Zealand) during the 1980s [17–19].
Comparative effectiveness or safety studies assess the differential benefit of a treatment in broad patient
categories to inform a clinical or policy decision by providing evidence for adoption of the intervention
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into a real-world setting [20, 21]; e.g. The Salford Lung Study (a pragmatic RCT) [9, 10, 22], the Novel
START study [23] and the Lung Health Study [24].
In practical terms, real-world studies complement results from RCTs by providing a higher external
validity once the efficacy and safety of a treatment has been confirmed under the strictly controlled
conditions of an RCT [5, 8]. Tools, such the PRECIS-2, are available to describe the representativeness of a
clinical trial compared with a real-world setting and are a valuable resource [25]. In addition,
observational studies can be used to investigate aspects that RCTs cannot, such as prevalence and
incidence of disease, aetiology, defining prognoses, disease impact, and burden and cost-effectiveness of
treatment. Table 1 shows select examples of findings from real-world asthma and COPD data highlighting
the different research questions that can be asked from pure observational studies and pragmatic trials
covering treatment choice, the use of inhalers, biomarkers and clinical disease history.
Principal causes and factors associated with forced expiratory volume in 1 s decline, COPD and
asthma, as established from observational studies
The principal causes and factors associated with forced expiratory volume in 1 s (FEV1) decline, COPD
and asthma, as established from previous observational studies, are listed in table 2. Carefully conducted
longitudinal studies have been instrumental in establishing causal relationships in obstructive lung disease,
with case–control and cohort studies in the 1950s and 1960s firmly establishing cigarette smoking as the
single greatest risk factor for lung cancer [48–50]. More recently, ECLIPSE (Evaluation of COPD
longitudinally to identify predictive surrogate endpoints), a longitudinal study, was devised with the aim of
describing the subtypes of COPD, defining predictive or surrogate markers of disease progression and,
potentially, novel targets for therapeutic intervention [15].
Despite having plateaued and even fallen in some regions, globally the prevalence of asthma has been
increasing rapidly for several decades [51]. There is a strong genetic component in asthma, demonstrated
by concordance of approximately 50% in monozygotic twins with asthma [52]; however, the speed of the
increase in prevalence is thought to be too high to be accounted for by a genetic change alone and is
therefore more likely to be related to environmental changes [53].
Comparing guidelines, RCTs and observational study outcomes in obstructive lung
disease
Treatment options
Results from RCTs have indicated a benefit of adding low-dose oral theophylline to inhaled corticosteroid
(ICS) therapy for COPD [94, 95]; however, UK National Institute for Health and Care Excellence (NICE)
guidelines for COPD do not recommend theophylline as the first-choice of treatment [96], and the Global
Initiative for Chronic Obstructive Pulmonary Disease (GOLD) report states that there is only limited and
contradictory evidence for the use of low-dose theophylline [97]. In addition, results from the TWICS
(theophylline with inhaled corticosteroids) pragmatic trial found no benefit of theophylline added to ICS
over placebo in a real-world setting [46]. Similarly, a systematic review of RCTs for asthma demonstrated
the superiority of ICS over leukotriene receptor antagonists (LTRA) for the management of asthma [98];
however, the ELEVATE (A pragmatic randomised single-blind controlled trial and economic evaluation of
the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma
guidelines) pragmatic study found no difference in effectiveness between ICS and LTRA [45]. These
seemingly conflicting findings may be due, in part, to the different patient populations included and the
lower adherence rate with ICS versus LTRA [45, 99].
In terms of treatment reduction, the Global Initiative for Asthma (GINA) recommends stepping down
ICS/long-acting β2-agonist (LABA) dose once asthma control has been achieved for ⩾3 months [100].
However, the FFLUX (A randomised pragmatic trial of changing to and stepping down fluticasone/
formoterol in asthma) pragmatic trial that investigated the stepping-down of treatment in patients who
were stable following 12 weeks of treatment, found that patients with a history of one or two exacerbations
within 12 months prior to starting treatment were at increased risk of re-exacerbation [44]. This highlights
the need for research beyond the outcomes of efficacy RCTs to be considered when guidelines are
developed and in this specific case, the need for asthma exacerbation history to be considered in guiding
clinicians in stepping-down of treatment.
Until relatively recently, the recommended treatment for asthma has been ICS maintenance treatment with
as-needed short-acting β2-agonists (SABAs) [101]. However, real-world data have found that patients
typically underuse ICS and overuse SABA [102]. This has led to the observation that overuse of SABA is
associated with an increase in all-cause mortality risk in patients with asthma [103]; the subsequent
revision of the guidelines to recommend combined ICS/SABA as needed demonstrates how the outcomes
of observational studies are influencing global guidelines [100].
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TABLE 1 Examples of findings from real-world asthma and COPD data highlighting the different research questions that can





Patient population Ecology of care Findings
Pure observational studies
Treatment choice
BUHL et al. [26]
DACCORD study
Question:
What is the comparative
effectiveness of dual
bronchodilation versus




• ⩾40 years initiating or
switching maintenance
therapy.
• Diagnosed with COPD
confirmed by spirometry.






• No intervention beyond
data-taking and
standard care.





• Exacerbation rate was
highest in patient who
was already on triple
therapy.








clinical symptom score in
patients with severe to
very severe COPD?
Comparator:
6 months after initiation
versus time of initiation.
• Patients with severe to very
severe COPD.
• Patients eligible for
roflumilast treatment as
indicated on drug label.











6 months after initiation.
Mixed inhaler devices










Changing to pMDI versus
remaining on DPI.
• 12–80 years.
• ⩾2 prescriptions of FDC ICS/
LABA DPI and no pMDI
prescription at baseline.
• Change to same ICS dose as
baseline dosage.
• Have not received multiple
different FDC ICS/LABA or
separate ICS and LABA at
index date.
• Historical cohort study.
• No intervention.













• ⩾40 years from primary care
record.
• Coded diagnosis for COPD.
• Historical cohort study.
• No intervention.
• Patients prescribed with
mixed inhaler devices
(DPI and pMDI) for
reliever and controller




PRICE et al. [30] Question:
What is the comparative
effectiveness of initiating
with the same BAI device
for asthma controller and
reliever therapy versus
mixed BAI and pMDI for
primary care patients?
• 4–80 years from primary care
record.
• Had coded diagnosis for
asthma, ⩾2 prescriptions for
asthma in the past year
(baseline), or ⩾2
prescriptions for asthma,
including one ICS, at one year
after initiation (index date).
• Excluded patients >60 years




therapy at baseline or LABA
at index date.
• Historical cohort study.
• No intervention.
• Patients prescribed the














Patient population Ecology of care Findings
Pure observational studies
Inhaler device type
PRICE et al. [31] Question:
What is the comparative
effectiveness of pMDI
versus DPI for delivery of






• 4–80 years from primary care
record.
• Coded diagnosis of asthma or
⩾2 prescriptions for asthma
medication (⩾1 ICS) at 1-year
baseline.
• ⩾1 prescriptions for asthma
at baseline.
• Excluded patients with a
diagnosis code for other
respiratory diseases.
• Historical cohort study.
• No intervention.






JONES et al. [32] Question:









• ⩾35 years from primary care
record.
• Coded diagnosis for COPD,
FEV1/FVC <0.7, and ⩾2
prescriptions of FP/SAL.
• Excluded patients with
chronic respiratory disorder
aside from COPD, asthma or
bronchiectasis.
• Excluded patients receiving
maintenance OCS or ICS at
baseline.
















What is the prevalence of
inhaler usage errors, in
terms of technique and
timing of usage, over
time in patients with
asthma or COPD?
• Patients with asthma or
COPD prescribed twice-daily
preventer inhaler.






• Patients were aware that




• Based on the audio
recording of inhaler
usage, only a minority of
patients had good
inhaler technique and












• >18 years with asthma and
COPD, using inhalers for
⩾1 month.











common in patients with
asthma than COPD.




duration of inhaler use.
MELANI et al. [35]
GENEBI project
Question:




referred to chest clinics,




• >14 years old regularly using
inhaler.








• Inhaler technique errors

















Patient population Ecology of care Findings
Pure observational studies
PRICE et al. [36]
CRITIKAL study
Question:




• >16 years old with asthma.
• Receiving FDC ICS/LABA via
DPI or pMDI.
• Excluded patients with other
respiratory diseases.
• Excluded patients who had
received OCS or antibiotics in




















ZEIGER et al. [37]
PREDUNA study
Question:
Is higher blood eosinophil





• Patients with ⩾2 years of
persistent asthma.
• Excluded patients with COPD
and other selected chronic
diseases.
• Historical cohort study.
• No intervention.
• Higher blood eosinophil
count was a risk factor
for higher risk and
increased rate of future
asthma exacerbations and
increased SABA use.









• Diagnosis code for asthma
and dispensed maintenance
therapy.
• No other chronic respiratory
disease in the past 3 years.
• No visit to the clinic of the




• Patients were managed
under standard care,






had similar risk of
developing asthma





• Asthma exacerbation rate








Is there an association
between blood eosinophil
count during a stable
COPD period and future
exacerbation rate in a
broad COPD population?
• ⩾40 years from primary care
record.
• Coded diagnosis for COPD,
• FEV1/FVC <0.7 within the past
5 years.
• History of smoking and no
other chronic respiratory
disease.
• Historical cohort study.
• No intervention.




• Association was limited
to ex-smokers.
PRICE et al. [40] Question:
What is the association
between blood eosinophil
count and prospective
asthma outcomes in the
general asthma
population?
• 12–80 years from primary
care record.
• Coded diagnosis of asthma.
• Excluded patients with other
chronic respiratory disease or
lacking information on
smoking status.
• Historical cohort study.
• No intervention.





odds of achieving asthma
control.
Clinical history of disease
JONES et al. [41] Question:
What are the patterns of
healthcare utilisation and
comorbidities in the years




• ⩾40 years from primary care
record.
• Recorded diagnosis of COPD
and ⩾2 prescriptions for
COPD-related drugs following
diagnosis.
• Historical cohort study.
• No intervention.




20 years prior to COPD
diagnosis, especially in






















• Diagnosis of active asthma.
• Historical cohort study.
• No intervention.







• Female patients had, in
general, more
comorbidities.
• Some comorbidities were
more commonly found in
either sex- or
age-specific groups.











• Receiving GINA Step 5
treatment or uncontrolled
















USMANI et al. [44]
FFLUX trial
Question:
What is the impact of
stepping-down FP/FOR
FDC ICS/LABA dosage on





stepping down to 500/
20 µg.
• 18–75 years.
• Diagnosis of asthma.
• Must have demonstrated
sufficient inhaler technique.
• Recruited from multiple
primary care centres across
England.
• Excluded patients with other
chronic respiratory diseases,
those who had severe asthma
or uncontrolled asthma prior
to recruitment.
• Open-label trial.















• Patients with a history of
asthma exacerbation




PRICE et al. [45]
ELEVATE trial
Question:
What is the effectiveness
of LTRA versus ICS as
initial asthma controller





• Physician diagnosis of
asthma.




asthma-related quality of life
or asthma control.









• LTRA was equivalent to
ICS as the initial
controller therapy in
terms of quality of life.






What is the effectiveness








• LTRA was equivalent to
LABA as the add-on
therapy in terms of
quality of life.
• Patients initiated with
LTRA had a significantly

















treatment reduce the risk









• Coded diagnosis of COPD,
FEV1/FVC <0.7.
• Smoking history of
>10 pack-years.
• Currently using ICS.
• ⩾2 exacerbations in the
previous year.
• Excluded patients with other
chronic respiratory diseases,





• No other change in
patient care other than
receiving theophylline/
placebo.










What is the effectiveness
of initiating open-label,
once-daily FF/VI in DPI




care in a general practice
setting?
Comparator:
FF/VI DPI versus standard
care.
• ⩾40 years.
• Documented diagnosis of
COPD.




• No restriction on smoking
status or lung function.
• No exacerbations during the
past 2 weeks.
• No long-term OCS use.
• Open-label trial.
• Primary care setting.
• Patients allowed to
continue previous LAMA
treatment.
• Patients trained for
correct inhaler usage
and technique.
• Patients in standard
care not permitted to
switch to FF/VI.
• Trial staff and doctors
received training on trial
procedures.
• Patients managed under
standard care.
• Patients initiated on FF/
VI had a significantly




• There was no difference






What is the effectiveness
of initiating open-label,






FF/VI DPI versus standard
care.
• ⩾18 years.




• No history of COPD.
• No restriction on smoking
status or lung function.
• Open-label trial.
• Primary care setting.
• Patients trained for
correct inhaler
technique.
• Patients managed under
standard care.
• Patients allowed to modify
treatment, aside from
initiating FF/VI within the
standard care group.
• Trial staff and doctors
received training on trial
procedures.
• Patients initiated on FF/
VI were significantly




• There was no difference
in the rate of serious
adverse events.
Biomarkers
PRICE et al. [47]
NSRS study
Question:
What is the value of FeNO
in predicting response to




• Patients had non-specific
persistent respiratory
symptoms.
• Never diagnosed or received







• Patients managed under
routine care similar to
patients with suspected
asthma.
• Analysed per protocol.
• There was a significant
interaction between FeNO
level and change in asthma
control measure following
treatment with extrafine
ICS, suggesting FeNO as a
valuable marker to predict
ICS response in patients
with non-specific
respiratory symptoms.
BAI: breath-actuated inhaler; COPD: chronic obstructive pulmonary disease; DPI: dry powder inhaler; FDC: fixed-dose combination; FeNO:
fractional exhaled nitric oxide; FEV1: forced expiratory volume in 1 s; FF/VI: fluticasone furoate/vilanterol; FOR: formoterol; FP: fluticasone
propionate; FVC: forced vital capacity; GINA: Global Initiative for Asthma; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LAMA:
long-acting muscarinic antagonist; LTRA: leukotriene-receptor antagonist; OCS: oral corticosteroid; pMDI: pressurised metred-dose inhaler;
PEF: peak expiratory flow; RCT: randomised controlled trial; SABA: short-acting β2-agonist; SAL: salmeterol.
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Real-world data may also provide complementary evidence to support findings from RCTs. The Salford
Lung Study pragmatic trial successfully demonstrated the real-world effectiveness of fluticasone furoate/
vilanterol treatment for maintenance therapy of COPD [10] and asthma [9], adding to the findings from
previous RCTs.
Some studies have also suggested limited value or even harm of certain therapies in COPD. An
observational nested case–control study of patients with COPD being treated with LABA and ICS from
TABLE 2 The principal causes and factors associated with FEV1 decline, COPD and asthma, as established from observational
studies
Cause Effect on FEV1 decline and/or COPD
1. Smoking • The only environmental risk factor whose contribution to COPD is entirely undisputed [48–50]; up to
half of all smokers eventually develop fixed airflow limitation [54].
• Smoking during pregnancy increases risk of low birth weight and decreased lung function at birth,
leading to lower maximum FEV1 and increased risk of impaired pulmonary function and developing
COPD in later life [55–58].
• Adolescents who smoke show reduced development of lung function [59].
2. Occupational exposure to dust
and gases
• Leads to accelerated decline in FEV1 and increased incidence of COPD [60–62].
• Dose–effect relationship between the number of agents to which subjects were exposed and decline
in FEV1 [63].
3. Burning of solid fuels/biomass • Linked to an increased risk of developing respiratory symptoms and airflow limitation [64, 65]; rate of
FEV1 decline slower and more homogeneous versus smokers [66].
4. Socioeconomic status and poverty • Strong risk factor for obstructive lung disease [67–69].
• Specific link not known, but likely to include multiple aspects throughout life, including environment,
diet, housing conditions and other lifestyle and occupational factors [70].
5. Chronic bronchitis • Strong association between chronic bronchitis/chronic mucus hypersecretion and FEV1 decline,
COPD-related morbidity and both overall and COPD-related mortality [71–73].
• Most important in patients <50 years of age [74].
6. Airway hyper-responsiveness • Known independent risk factor for COPD [75, 76].
• Occurrence during young adult life associated with an increased risk of COPD 20 years later [75].
7. Asthma • Uncontrolled asthma leads to airway remodelling and fixed airflow obstruction that may lead to an
incorrect diagnosis of COPD [77] .
Cause Effect on asthma
1. Exposure to microorganisms • Viral infection is one of the most common causes of asthma exacerbations [53].
• Exposure in early life is associated with an increased risk of developing persistent asthma in later
life [53]; however, reduced exposure during childhood may be contributing to the global increase in
allergy and asthma [52].
2. Allergen exposure • Childhood asthma is typically attributed to an allergic sensitisation [52, 53].
• The risk of allergic sensitisation may differ between allergens and may be related to the dose and
duration of exposure [52, 53, 78].
3. Smoking (active and passive) • Passive smoking, both pre- and post-natal, is associated with an increased risk of asthma in
children [79].
• Passive smoking is also associated with a higher prevalence of asthma and bronchial responsiveness
in adults [80].
• An association between active smoking and onset of asthma may be stronger in younger than older
adults [81].
4. Air pollution • Exposure to traffic-related air pollution during early childhood is associated with a higher risk of
developing asthma in later life [53].
• An association between outdoor nitrogen levels and the onset of asthma has been observed in
adults [82].
5. Indoor environment • Dampness in residential buildings has been associated with the onset of asthma in both children [83]
and adults [84]; this problem may well extend to the workplace [84].
6. Occupation • Occupational exposure is estimated to account for approximately 15% of new asthma diagnoses in
adults [85].
• Cleaners, welders and farm workers in particular are at increased risk [86–88].
7. Diet • Low intake of vitamin C and fruit has been associated with a higher risk of asthma [89].
• A lower prevalence of wheeze and risk of asthma has been observed in children receiving a
Mediterranean diet and fish in early childhood [89].
8. Obesity • Obesity is a risk factor for developing asthma in both children and adults [90, 91].
• The mechanism is not completely understood, but obesity-induced systemic inflammation [90, 92]
and decreased physical activity may both play a role [93].
COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s.
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registry data over 4.5 years found that the addition of the long-acting muscarinic antagonist (LAMA)
tiotropium was associated with an increased cardiovascular risk in patients with COPD [104]. However,
none of the recent fixed triple combination registration trials have seen this effect and in the three-year
ASCENT (Evaluate the effect of aclidinium bromide on long-term cardiovascular safety and exacerbations
in moderate to very severe COPD patients) RCT of patients with COPD and high cardiovascular risk,
there was no increase in the risk of cardiovascular events for patients receiving the LAMA aclidinium
compared with placebo [105].
Inhaler device, technique and adherence
RCTs typically ensure that patients demonstrate correct inhaler technique and adhere to their treatment;
thus, results from RCTs reflect the efficacy of inhalers under a near-perfect technique and adherence rate
[106, 107]. However, inhalation errors in a real-world setting have been shown to increase the risk of poor
treatment outcomes, such as hospitalisation, medication use and symptom control [35, 36, 107]. In
addition, mixing inhaler devices may lead to worse COPD outcomes than when single devices or devices
requiring the same inhalation technique are used [29, 30]. Thus, results from real-world studies emphasise
the importance of ensuring proper inhaler technique to maximise treatment success in both asthma and
COPD. Other examples of findings from real-world evidence in asthma/COPD can be found in table 1.
With regard to specific inhaler types, according to the recommendations of the British Thoracic Society
Scottish Intercollegiate Guidelines Network [108] and results from interventional RCTs, dry powder
inhalers (DPI) are as effective as pressurised metered-dose inhalers (pMDI) for the delivery of ICS
treatment [109, 110]. This is supported by a recent study utilising the Korean Health Insurance Claims
database, which found a comparable clinical and cost efficiency between patients with asthma who
switched from a DPI to a pMDI versus patients who remained on a DPI [28]. However, other results have
been more conflicting [35, 36, 106, 107, 111] and real-world studies from the UK have suggested that
pMDIs are superior to DPIs in both asthma [31] and COPD [32], illustrating that the outcomes of
observational studies can still be conflicting and the importance of understanding the different
methodologies and analyses used.
Weaknesses of observational studies
It is important to note that despite the many advantages of observational studies, as with all study designs,
the methodologies employed are subject to specific biases, including selection bias (systematic differences
between baseline characteristics of the groups that are compared) and detection bias (systematic differences
between groups in how outcomes are determined) [112]. Studies utilising electronic health records are
further susceptible to a degree of inaccuracy and incompleteness; such records are typically collected for
routine medical purposes and can lack the quality, detail and accuracy typically required for research
purposes [113].
In enrolling a broad patient population, the analysis of data generated from observational studies is
complicated by confounding factors such as confounding by indication; i.e. most patients receiving
medication in an observational study have been formerly diagnosed by a doctor whereas those without the
medication have not, despite otherwise appearing almost identical [114]. Another factor which must be
considered is the avoidance of immortal time balance, which can be the consequence of incorrect handling
of the period between study entry and treatment initiation in time-to-event analyses [115]. For
time-dependent confounders, such as body mass index, which is a risk factor for asthma that may lead to
reduced physical activity and is also affected by prior levels of physical activity, the parametric g-formula
can be used in place of conventional regression approaches [116, 117].
Biases in observational studies can be significantly reduced by using a prospective study design and a
predefined statistical analysis plan [5, 118]. In addition, tools such as the Risk of Bias in Non-randomised
Studies of Interventions (ROBINS-I) [119] and Newcastle-Ottawa Scale (NOS) for assessing the quality of
non-randomised studies [120] may also be beneficial in minimising bias. However, while statistical
adjustment and matching can be used to minimise confounding effects [5, 118], factors which are not
accounted for, and thus not recorded within the study, are likely to remain. It should be noted that RCTs
are often also affected by bias, such as selection and information bias, although this is not always
recognised.
Markers of quality for observational studies
Despite their shortcomings, clinical guidelines still place a greater emphasis on results from classical RCTs
than from observational studies [8]. Indeed, traditional tools for rating quality of studies such as the
Grading of Recommendations, Assessment, Development and Evaluation (GRADE) also downgrade
observational study designs [8].
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To achieve greater integration of real-world evidence into the development programmes of new drugs, it is
vital that observational studies are subjected to standards that are as equally rigorous as those devised for
classical RCTs [8]. There is, therefore, a need to standardise the quality of real-world evidence. Recently, a
joint task force between the Respiratory Effectiveness Group and the European Academy of Allergy and
Clinical Immunology (EAACI) developed a standardised tool for quality appraisal of comparative
effectiveness studies, the REal Life EVidence AssessmeNt Tool (RELEVANT; www.regresearchnetwork.org/
relevant-tool-2) [121]. The tool incorporates 21 quality checklist items, of which 11 primary items
determine a study’s suitability for guideline development and 10 secondary items are for general appraisal
of the study. Quality appraisal using the RELEVANT tool on selected examples of comparative
effectiveness studies are presented in table 3; similar tools are already available for evaluating observational
studies [122, 123].
Why we need both RCTs and observational studies
Comparing RCT and observational study data by adjusting and aligning patient data has further
highlighted the importance of using both study types to assess the effect of a treatment. A number of
studies on the use of statins in patients with COPD have indicated that statins may provide additional
benefits in terms of improving lung function and reducing risk of exacerbation, hospitalisation and death
[124–126], potentially through reduction of inflammation [127]. Of particular interest, the
STATCOPE (Simvastatin for the prevention of exacerbations in moderate-to-severe COPD) RCT found
that statins had no impact on exacerbation risk, lung function, or on general or disease-specific quality of
life in patients with COPD [128]. In contrast, an observational study by INGEBRIGTSEN et al. [129] found
that statins did reduce exacerbation risk. However, when these same observational data were adjusted to
align the patients with those from the STATCOPE RCT, statins were found to provide no additional
benefit in patients with COPD. Due to the inherent differences in the patient populations of RCTs
and observational studies, as previously described, this finding clearly demonstrates why both RCTs and
observational studies are needed to form a complete picture of treatment effect.
Future prospects in real-world evidence in asthma/COPD
Several complex observational studies in asthma/COPD have contributed to a greater understanding of the
heterogeneity of the asthma/COPD population in a real-world setting, including COPDGene [130],
ECLIPSE [15], SPIROMICS (Subpopulations and intermediary outcomes in COPD study; U-BIOPRED:
Unbiased biomarkers in prediction of respiratory disease outcomes) [131] and U-BIOPRED [132]. These
studies have led to an increasing recognition of the importance of personalised healthcare and the value of
endotype-driven assessment and management [133]. However, to date, both RCTs and real-world studies
have largely examined the effects of pharmacological treatment at a population level. Thus, although
treatment has been shown to have a statistically significant impact on symptoms, exacerbations and airflow
obstruction, the scale of the effects at the group level are often limited, suggesting that not all patients may
gain the same effect from treatment. Thus, as we enter an era of personalised medicine, there is a need to
identify the individual patient factors that are associated with treatment response.
The recent shift towards a treatment approach guided by treatable disease characteristics, or traits [134],
that is less dependent on conventional diagnostic labels, has highlighted a lack of studies that span both
TABLE 3 Author’s appraisal of selected comparative effectiveness studies using RELEVANT 2.0 tool [121]
Author and study name Study design Primary item score n out of 11 (%) Secondary item score n out of 10 (%)
VESTBO et al. [10]
Salford Lung Study
Pragmatic RCT 10 (91%) 8 (80%)
BOSNIC-ANTICEVICH et al. [29] Historical matched cohort
study
11 (100%) 8 (80%)




10 (91%) 8 (80%)
KARDOS et al. [27]
DINO and DACOTA studies
Prospective observational
cohort studies
10 (91%) 10 (100%)
OCAKLI et al. [34] Cross-sectional observational
study
8 (73%) 5 (50%)
ZEIGER et al. [38] Prospective observational
study
11 (100%) 6 (60%)
RCT: randomised controlled trial.
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COPD and asthma across a broad range of severities. In order to provide a greater understanding of the
value of a personalised healthcare approach in patients in clinical practice, there is a need for large-scale,
inclusive observational studies with standardised outcome measures and a focus on patient-reported
outcomes, physician assessments, airway physiology and blood and airway biomarkers across both primary
and specialist care. The NOVEL observational longiTudinal studY (NOVELTY) study (NCT02760329) is
one such study that aims to address this need [135]. NOVELTY is a global (19 countries), 3-year
prospective, observational study of >12000 patients with a diagnosis or suspected diagnosis of asthma and/
or COPD that aims to describe patient characteristics, treatment patterns and burden of illness, and to
identify the clinical phenotypes and molecular endotypes (based on biomarkers and/or clinical parameters)
that are associated with differential outcomes for symptom burden, clinical evolution and healthcare
utilisation over time. It is expected that the majority of patients enrolled in NOVELTY would not have
been eligible for inclusion in most RCTs, therefore NOVELTY offers the prospect of investigating disease
mechanisms and outcomes in a more clinically relevant population than that provided by a classical RCT.
Conclusions
Real-world evidence is capable of providing valuable insights into disease mechanisms and management;
however, due to the potential for producing large amounts of data and analyses compared with RCTs, it is
vital that they are designed with clear research questions in mind. These research questions may demand
different methodologies and, as such, will guide the type of study that is required. This will help to
challenge perceptions that real-world evidence is solely for the evaluation of safety/epidemiology, and will
demonstrate that they can also inform on patient outcomes if designed with clear research questions.
Furthermore, due to the inclusion of a broader range of patients than RCTs, real-world studies require a
much greater understanding of confounders and modifiers of effects compared with RCTs to aid
interpretation of their findings.
Observational real-world studies are a vital component of research into obstructive lung disease, and
well-designed observational studies can support pivotal RCTs and provide evidence that has the potential
to influence clinical practice. Although observational studies are subject to specific challenges, with the aid
of recently developed quality standard tools, these challenges can be factored into study design to produce
high-quality results. In future, well-designed, real-world studies that include a broad range of patients (in
terms of geographical location, care setting and severity level) across both asthma and COPD diagnoses
will be instrumental in supporting a more personalised, endotype-driven approach to the assessment and
management of patients with obstructive lung disease.
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